SELLAS Life Sciences Group Inc buy BiotechBee
Start price
08.09.24
/
60%
€1.09
Target price
30.04.27
€1.50
Performance (%)
-21.73%
End price
14.12.24
€0.85
Summary
This prediction ended on 14.12.24 with a price of €0.85. The prediction for SELLAS Life Sciences Group Inc disappointed with a performance of -21.73%. BiotechBee has 60% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| SELLAS Life Sciences Group Inc | 15.600% | 15.600% | 108.163% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% |
According to BiotechBee what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year